This is a case series of patients suffering from neurotrophic keratopathy. The main categorisation of the disease is dis cussed as well as the management that should be followed on each stage. Several cases of patients with neurotrophic keratopathy are analysed and the treatment (different on every patient) of them is presented. Newer substances that are beginning to be used in the treatment of neurotrophic keratopathy are discussed as well.
introduCtion
Neurotrophic keratopathy is a degenerative dis ease that is characterised by reduction of corneal sensitivity. In neurotrophic keratopathy, the corneal innervation that is procured to the cornea by the trigeminal nerve is impaired. Neurotrophic kerato pathy is estimated to affect less than 50/100,000 in dividuals [1] .
Every condition, ocular or systemic, that alters corneal sensory innervation (from the cornea itself to the trigeminal nerve) can cause neurotrophic keratopathy. Some of the most common conditions that can lead to neurotrophic keratopathy are herpes keratitis (simplex and zoster), contact lens overuse, topical anaesthetic abuse, chemical and physical burns, topical drug toxicity, and corneal and ocular surgery.
When it comes to corneal surgery, there have been studies [2, 3] indicating that both Photore fractive Keratectomy (PRK) and laser in situ ker atomileusis (LASIK) can potentially cause nerve damage. However, the chances of something like this happening are higher [4, 5] in LASIK surgery. Deep anterior lamellar keratoplasty [6] (DALK) and penetrating keratoplasty (PK) can also cause a degree of corneal insensitivity. In patients with keratoconus [7] , who have undergone corneal col lagen crosslinking, a reduction of corneal sensitivity occurs as well.
Laser for the treatment of proliferative diabet ic retinopathy has also been reported [8] to cause neurotrophic keratopathy. Vitrectomy (for retinal detachment) and photocoagulation to treat diabetic retinopathy have been reported [9] to cause neu rotrophic keratopathy, as well. Also, neurosurgical procedures [10] or trauma damaging the fifth cra nial nerve, intracranial tumours, multiple sclerosis, aneurisms, and stroke can cause neurotrophic ker atitis. Diabetes, vitamin A deficiency, and leprosy have also been linked [10] to neurotrophic kerato pathy.
During clinical examination, many histological alterations may be observed. Thinning or disruption of the epithelial layer, swelling of the epithelial cells, disorganisation of Bowman's membrane, stromal melting, or scarring and neovascularisation are sev eral of them. Conjunctiva is usually also involved with the reduction in the density of goblet cells. www.journals.viamedica.pl/ophthalmology_journal
The highly concerning thing about neurotroph ic keratopathy is that patients usually do not seek medical opinion, due to the lack of sensitivity on the cornea, thus the lack of ocular surface symp toms, and the disease progresses until they do, months or maybe years after its first manifestation.
Starting the clinical evaluation, the physician should evaluate corneal sensitivity, when neuro trophic keratopathy is suspected. Subsequently, cor neal staining with fluorescein should be performed in order to check for epithelial deficits. A Schirm er test could also be useful in order to determine whether the tear production has been compromised due to reduction of corneal sensitivity. Finally, in order to rule out any chance of infection, corneal culture should be performed.
Based on its symptoms, neurotrophic keratopa thy can be categorised in three stages, known as the "Mackie classification" [11] :
Stage 1: this stage is manifested by hyperplasia or irregularity of the corneal epithelium that can evolve to punctate keratopathy, corneal oedema, stromal scarring, and neovascularisation.
Stage 2: this stage is presented with recurrent and persistent epithelial defects, most commonly in the superior half of the cornea. These defects are usually ovalshaped and their margins are smooth and rolled due to the impaired epithelial healing.
Stage 3: in this stage, there is involvement of the stroma, which leads to corneal ulcer, melting, and corneal perforation.
When managing neurotrophic keratopathy, the main purpose is to promote corneal healing without any complications. Topical nonsteroidal antiin flammatory drugs (NSAIDs) [12] should be avoid ed because they do not show any improvement in patients with neurotrophic keratopathy and they can further decrease the sensitivity of the cornea. The management in stage 1 of the disease, where punctate keratopathy is clinically observed, is with frequent application of preservativefree artificial tears and lubricant ointments. The main purpose is to improve the quality of the epithelium and avoid epithelial breakdown. In cases where punctate kera topathy is persistent, autologous serum [13, 14] can be used, as well as a therapeutic soft contact lens.
In stage 2, the main purpose of management is to heal the persistent epithelial defects and prevent the formation of corneal ulcers. The treatment usu ally includes plenty of artificial tears and lubricant ointments, autologous serum use, amniotic mem brane [14] graft, or tarsorrhaphy, if needed, in order to manage the epithelial defects. Because the epithe lium is open, antibiotic drops can be prescribed in order to prevent infections [1] .
In stage 3, the treatment is focused on the pre vention of corneal perforation. In addition to the treatment used for stages 1 and 2, in stage 3 oral dox ycycline, medroxyprogesterone, can be prescribed if stromal melting is observed [15] . A ReGeneraT ing Agent (RGTA) polymer [16] eye drop has also proven to be successful in treating persistent neu rotrophic ulcers. Similarly, a recombinant version of human nerve growth factor (Cenegermin) [17] has been proven to restore the normal healing pro cess of the eye and repair corneal damage for pa tients with moderate to severe neurotrophic kera topathy and has recently been granted approval for use in Europe [17] .
If, despite all efforts, perforation of the cornea occurs, the treatment varies and depends on its size. If it is small, cyanoacrylate glue can be applied, along with a soft contact lens. If the perforation is larger, a conjunctival flap procedure can be per formed or even a lamellar keratoplasty, depending on the severity of the case.
Case reports
These are the case reports, presenting several dif ferent patients with neurotrophic keratitis and the pattern we chose to treat them.
patient 1
The first patient was male, 66 years old. He was diagnosed with Sjögren's syndrome and severe acne rosacea that intensified the severe blepharitis he al ready had. The patient had a history of recurrent neurotrophic ulcers in both eyes. The patient was thoroughly examined by Dr Mallias (with slit lamp and anterior optical coherence tomography [OCT] as shown in Figures 1 and 2) . He was diagnosed with keratoconjunctivitis sicca on the right eye and a sterile corneal ulcer on the left eye (Fig. 1) , and his best corrected visual acuity (BCVA) was 20/30 in the right eye and 20/200 in the left eye.
The patient was treated with ample artificial tears and an antibiotic (preventively), and a contact lens was placed. After three days the patient felt slightly better and the contact lens was removed, but he returned a few days later complaining of pain and severe loss of visual acuity. The slit lamp exam ination revealed corneal perforation and reflux of blood of Schlemm's canal due to hypotony (Fig. 2) . www.journals.viamedica.pl/ophthalmology_journal Dr Mallias then proceeded with a conjunctival flap procedure and, after two weeks, a successful penetrating keratoplasty procedure (Fig. 3) .
patient 2
The second patient was female, 64 years old, di agnosed with biopsyproven ocular cicatricial pem (Fig. 4) .
She underwent an emergency penetrating kera toplasty (Fig. 5) of the left eye due to eminent risk of corneal perforation.
The patient developed a nonhealing epithelial defect five months after penetrating keratoplasty in her left eye (Fig. 6) . Artificial tears and a bandage soft contact lens were applied, and oral doxycycline was prescribed.
Despite the treatment the epithelial defect expand ed and covered more than half of the corneal surface (Fig. 7) . Cortical steroids were discontinued and oral valacyclovir was initiated at 500 mg twice a day. www.journals.viamedica.pl/ophthalmology_journal Despite the change of medical treatment, epi thelialisation was not achieved. At that point, the decision to start the patient on RGTA polymer eye drop was made. The dosage was one drop every other day. Several days after treatment initiation, the epithelium healed and the patient's visual acuity improved significantly (Fig. 8) .
patient 3
The third patient was female, 87 years old. She complained about lacrimation and severe pain in her right eye. Her BCVA was 20/200 for the right eye and 20/25 for the left eye. Slit lamp and OCT examination revealed corneal melt with a small de scemetocele (area of the cornea with total melt of (Figs. 9 and 10) .
Dr Mallias then proceeded to treat with His toacryl glue (Figs. 11, 12 ) and a bandage soft con tact lens. The patient was instructed to instil ofloxa cin four times per day and preservative free artificial tears every two hours. The use of topical corticoster oids is contraindicated in such cases.
The Histoacryl glue remains on the cornea until healing is achieved. Then the glue usually falls out by itself disCussion Neurotrophic keratopathy is a complicated disease and should be treated carefully. Patients should be closely monitored due to the lack of corneal sensitiv ity. In order to make the diagnosis of neurotrophic keratopathy, corneal sensation should be evaluated. To test for corneal sensation there are qualitative and quantitative methods [18] . The most commonly used method in clinical practice, which is qualitative in na ture, is the use of a cottontipped applicator. A wisp of the cottontipped applicator is used to compare sen sation in each eye. It is recommended to approach the patient from the side and test all four quadrants. The www.journals.viamedica.pl/ophthalmology_journal Figure 12 . The right eye of the third patient after the Histoacryl glue placement sensation should be recorded in each location as: nor mal, reduced, or absent. Topical anaesthetics should not be used prior to testing corneal sensation. Cor neal esthesiometers could be used as well, such as the Handheld CochetBonnet esthesiometer [18] .
Artificial tears should be used frequently in order to smooth out the cornea in all the stages of the dis ease, and patients should be advised to be extra care ful to avoid infections because the corneal epithelium might be compromised. Even after treating the cur rent symptoms, patients should be extra careful and pay frequent visits to the ophthalmologist in order to make sure that the ocular surface remains healed.
Due to the nature of the disease, it is difficult to man age it with drugs because the preservatives that exist in them cause more harm than good on the ocular surface. This is the reason why scientists came up with the ReGen eraTing Agent (RGTA) eye drop and the recombinant version of human nerve growth factor (Cenegermin). Both of these substances promote epithelial healing.
RGTA [19] acts by playing the role of glycos aminoglycan, more specifically, heparin sulphate. The absence of glycosaminoglycan is associated with degradation of the extracellular matrix, which can result in corneal thinning, nonhealing epithelial defects, and inflammation. The RGTA agents restore the balance of matrix proteins and cytokines that are normally bound to heparin sulphate and ensure equilibrium in the corneal microenvironment. This prevents degradation of extracellular matrix proteins, and promotes stromal and, subsequently, epithelial healing. Cenegermin [17] or recombinant human nerve growth factor as mentioned above is an artifi cial form of a naturally occurring signalling protein, nerve growth factor (NGF). It aims to improve nerve function in the cornea and stimulate healing as well as bring back some of the lost sensation of the cor nea. RGTA agents have been further investigated and used in dealing with neurotrophic keratopathy. On the other hand, Cenegermin has recently been granted approval for use in Europe, thus the lack of published studies involving it. However, both substances promote epithelial healing to a reasonable degree. What would really be interesting is a study comparing these two agents in the treatment of neu rotrophic keratopathy, in order to find out which substance is of greater benefit for these patients. 
